Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 July 2020Website:
http://www.alxoncology.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
ALXO Latest News
ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Analysts' price targets for ALX Oncology Holdings (ALXO) suggest a potential 36.6% increase in the stock. Although this metric is not always reliable, the consensus among analysts in increasing earnings estimates does indicate a positive outlook for the stock.
ALX Oncology (ALXO) reports encouraging findings from a phase 1/2 trial of a potential combination therapy for the treatment of refractory or relapsed B-cell non-Hodgkin lymphoma, including both indolent and aggressive forms.
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leading to further gains for investors. ALXO also announced a cash raise of $55 million, reducing the need for a future cash raise and lowering the risk of dilution.
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the stomach and esophagus. The ASPEN-06 clinical evaluated the effectiveness of evorpacept in treating patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
What type of business is ALX Oncology Holdings?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
What sector is ALX Oncology Holdings in?
ALX Oncology Holdings is in the Healthcare sector
What industry is ALX Oncology Holdings in?
ALX Oncology Holdings is in the Biotechnology industry
What country is ALX Oncology Holdings from?
ALX Oncology Holdings is headquartered in United States
When did ALX Oncology Holdings go public?
ALX Oncology Holdings initial public offering (IPO) was on 17 July 2020
What is ALX Oncology Holdings website?
https://www.alxoncology.com
Is ALX Oncology Holdings in the S&P 500?
No, ALX Oncology Holdings is not included in the S&P 500 index
Is ALX Oncology Holdings in the NASDAQ 100?
No, ALX Oncology Holdings is not included in the NASDAQ 100 index
Is ALX Oncology Holdings in the Dow Jones?
No, ALX Oncology Holdings is not included in the Dow Jones index
When was ALX Oncology Holdings the previous earnings report?
No data
When does ALX Oncology Holdings earnings report?
The next expected earnings date for ALX Oncology Holdings is 07 March 2025